These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33104040)

  • 1. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
    Abbruzzese G; Kulisevsky J; Bergmans B; Gomez-Esteban JC; Kägi G; Raw J; Stefani A; Warnecke T; Jost WH;
    J Parkinsons Dis; 2021; 11(1):187-198. PubMed ID: 33104040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
    ; Bergmans B; Bourgeois P; Cras P; Dethy S; De Klippel N; Franco G; Garraux G; Geens K; Jacquerye P; Jeanjean A; Supiot F; Van der Linden C; Krygier C
    Acta Neurol Belg; 2023 Jun; 123(3):939-947. PubMed ID: 36201116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world data of a German Parkinson's disease population: effectiveness and safety of safinamide in routine clinical practice.
    Jost WH; Gluth I; Lück JC; Lopes OIFDC;
    Curr Med Res Opin; 2023 Dec; 39(12):1621-1628. PubMed ID: 37421634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
    Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
    Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy.
    Bovenzi R; Liguori C; Canesi M; D'Amelio M; De Pandis MF; Marini C; Monge A; Padovani A; Tessitore A; Stefani A; Zappia M;
    Neurol Sci; 2024 Feb; 45(2):573-583. PubMed ID: 37684511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real life evaluation of safinamide effectiveness in Parkinson's disease.
    Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
    Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safinamide: A Review in Parkinson's Disease.
    Blair HA; Dhillon S
    CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
    Kulisevsky J; Esquivel A; Freire-Álvarez E; Gómez-Esteban JC; Legarda-Ramírez I; Avilés A; Mata-Álvarez-Santullano M
    Rev Neurol; 2023 Oct; 77(s02):1-12. PubMed ID: 37752685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
    Perez-Lloret S; Rascol O
    Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
    Abbruzzese G; Barone P; Lopiano L; Stocchi F
    Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Abreu D; Ferreira JJ
    Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safinamide for symptoms of Parkinson's disease.
    Müller T
    Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Safinamide and Gender Differences During Routine Clinical Practice.
    Pellecchia MT; Picillo M; Russillo MC; De Pandis MF; Bonizzoni E; Marjanovic I; Cattaneo C
    Front Neurol; 2021; 12():756304. PubMed ID: 34970207
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
    Kurihara K; Mishima T; Fujioka S; Tsuboi Y
    Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R
    JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Aboulatta L; Haidar L; Abou-Setta A; Askin N; Rabbani R; Lavu A; Peymani P; Zarychanski R; Eltonsy S
    CNS Drugs; 2023 Nov; 37(11):941-956. PubMed ID: 37973769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.